Analysis of adverse reactions in blood system caused by fulvestrant
MA Bing-jie
WANG Yu
CANG Ai-jun
Abstract：Objective:To analyze the reports of hematologic adverse drug reactions(ADRs)induced by fulvestrant and investigate their clinical characteristics and risk factors.Methods:Cases of hematologic ADR associated with fulvestrant reported by our hospital from September 1,2021 to December 31,2023 were screened and analyzed to explore the features of these ADR.Results:The majority of patients who experienced ADRs were elderly individuals aged 70 years or older.The primary hematologic toxicities observed included leukopenia/neutropenia and thrombocytopenia,with two cases identified as new serious ADRs that had not been previously documented in the drug's prescribing information.Temporally,most ADRs occurred within 15 d after the first dose.Additionally,concomitant use of fulvestrant with CDK4/6 inhibitors(e.g.,abemaciclib)or anti-HER2 targeted therapies was found to potentially exacerbate hematologic toxicity.In terms of management,most patients showed significant improvement after symptomatic treatment,including drug discontinuation,granulocyte colony-stimulating factor(G-CSF)infusion,and thrombopoietin administration.Conclusion:Fulvestrant,whether used as monotherapy or in combination regimens,may induce myelosuppression,particularly in elderly patients and when co-administered with other drugs.Enhanced blood monitoring during initial treatment and updates to ADR warnings in the prescribing information are recommended to optimize clinical safety.
Keywords：fulvestrantthe blood systemadverse drug reactionrational use of drugs
Publication Date：2025-10-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：5( 2117-2121 )